Enjoy complimentary customisation on priority with our Enterprise License!
The acute ischemic stroke (AIS) therapeutics market is estimated to increase by USD 1,524.49 million between 2022 and 2027. The size of the market is forecast to grow at a CAGR of 5.72%. The growth of the market depends on several factors, including the rising prevalence of disease, the increasing adoption of NOACs, and the increasing prevalence of sedentary lifestyles.
To learn more about this report, Download Report Sample
The high-risk factors, such as obesity, atherosclerosis, hypertension, and old age are notably driving the market growth, although factors such as unmet needs for anticoagulant reversal agents may impede the market growth.
Key Driver
High-risk factors, such as obesity, atherosclerosis, hypertension, and old age are notably driving the acute ischemic stroke (AIS) therapeutics market growth. Cardiovascular diseases, particularly MI (myocardial infarction) and stroke are the leading causes of disability and death globally and are a major public health concern. AIS is the most common form of stroke that occurs when oxygen-rich blood supply to a part of the brain is blocked either by the formation of plaque or a blood clot. If not treated on time, a stroke can result in disability or even death. Therefore, quick and acute treatment with generic drugs such as alteplase is recommended within 3-4 hours after the onset of the first symptom of a stroke.
As per the Centers for Disease Control and Prevention (CDC), ischemic stroke accounts for approximately 87% of all strokes. Stroke is the second-leading cause of death globally. An ischemic stroke occurs when an artery carrying oxygen-rich blood to the brain is blocked by a blood clot. A transient ischemic attack is also a type of ischemic stroke and lasts for a short time of fewer than five minutes. This mini-stroke occurs when blood flow to the brain is blocked for a shorter duration. A transient ischemic attack (TIA) is generally a warning sign of a stroke in the future. One-third of people, who had an untreated transient ischemic attack, suffered a major stroke within a year. According to the World Stroke Organization, currently, 15-16 million people suffer from stroke globally, while 5.8-6 million people die from it. High-risk factors, such as obesity, atherosclerosis, hypertension, and old age, are the major contributors to the growth of the segment during the forecast period.
Key Trend
TBI, a value-addition in AIS research is the primary trend driving the market growth. AIS is a complex cardiac disease that requires the integration of various heterogeneous features originating from genotypic, phenotypic, and environmental sources. Modern approaches called translational bioinformatics (TBI) that can integrate and analyze these heterogeneous features are being developed to enhance the clinical guidelines for treating and preventing AIS. TBI is a computational technology that focuses on integrating and analyzing data obtained from bioinformatics, biostatics, statistical genetics, and clinical informatics. It acts as a data-storage source that not only enables data integration but also improves data representation by using tools such as Ontologies and Controlled vocabulary. These vocabulary tools provide a standard way for data representation, in which the data is accepted by specific user communities, such as Gene Ontology and the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT).
In AIS, the data element that requires integration refers to the presence or absence of a risk gene (HDAC9, PITX2, ZFHX3, NINJ2, PRKCH, and 9p21) in the genome of each patient (called genotypic data) with that of the clinical element, which is extracted from clinical tests (such as magnetic resonance imaging) of each patient, on which the physician relies. The compilation of all these details from each patient provides doctors with knowledge about the clinical scenario of each patient and a better approach to treatment.
Key Challenge
Unmet needs for anticoagulant reversal agents may impede the market growth. Though anticoagulants play an important role in treating AIS, they are sometimes associated with side effects such as excessive bleeding. The side effects can be reversed using reversal agents, which are referred to as antidotes for anticoagulants. The antidotes available in the market include vitamin K, protamine, and prothrombin complex concentrates, which reverse the action of warfarin and heparin. Though NOACs (novel oral anticoagulants) show better safety and efficacy profiles, the acceptability of these drugs is low due to the unavailability of antidotes in the market.
The limited availability of anticoagulant reversal agents in the market will limit the uptake of novel anticoagulants in the market. Recently, the reversal agent, idarucizumab, which acts as the antidote to dabigatran, was approved by the US FDA. Newer anticoagulants, such as direct thrombin inhibitors or Factor Xa inhibitors, do not have any specific reversal agents. Research is still underway for the development of reversal agents. Thus, the unmet need existing in the market for anticoagulant reversal agents limits the use of anticoagulants, thereby negatively affecting the market growth.
Key Market Customer Landscape
Our analysis of the Life Cycle of the Global AIS therapeutics market indicates a movement from the innovator’s stage to the laggard’s stage. The report illustrates the lifecycle of the market, focusing on the adoption rates of the major countries, including the US, Canada, the UK, Germany, and China. Technavio has included key purchase criteria, adoption rates, adoption lifecycles, and drivers of price sensitivity to help companies evaluate and develop growth strategies from 2022 to 2027.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market
Pfizer Inc- Under the unified segment, the company is engaged in the discovery, and development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide. The company's key offerings include acute ischemic stroke therapeutics such as Plavix.
We also have detailed analyses of the market’s competitive landscape and offer information on 20 market companies, including :
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the thrombolytics segment will be significant during the forecast period. The high market share of this segment is attributed to the availability of the US FDA-approved AIS therapeutic, IV alteplase, for the treatment of AIS in 1987. The drug, sold under the brand name Activase, is a tissue plasminogen activator and is used for multiple indications such as AIS, acute myocardial infarction (AMI), and acute massive pulmonary embolism (PE). IV (intravenous) administration of Activase remains the mainstay treatment for AIS. Activase produces improved neurological outcomes in a large number of AIS patients, which results in a high adoption rate among general physicians and patients, thus, bolstering market growth.
Get a glance at the market contribution of various segments Request a PDF Sample
The thrombolytics segment showed a gradual increase in market share, from USD 2,464.99 million in 2017 and continued to grow by 2021. As per the NIH, the therapeutic efficacy of alteplase, administered within 3-4 hours after the onset of initial symptoms of AIS, is 52.4% when compared with 45.2% for a similarly administered placebo. The extended time window for the administration of alteplase further increases the prescription value of thrombolytic drugs, thus driving the market growth. Furthermore, our report provides a brief analysis of the historical and forecast market share and their segments along with the reasons for growth from 2017 to 2027.
For more insights on the market share of various regions Request PDF Sample now!
North America is projected to contribute 38% by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The expected approval of late-stage pipeline molecules, such as BIIB093 (intravenous glibenclamide), BRILINTA, MultiStem, and NA-1, is also expected to boost market growth during the forecast period. North America is one of the most developed regions in the world. The market in the region, therefore, witnesses the availability of various diagnostics and drugs for the treatment of stroke. Despite the increasing use of stroke therapeutics in this region, the market faces a tough challenge from alternative treatment options.
Our report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by type, distribution channel, and region.
The Market encompasses treatments for one of the leading causes of disability and mortality worldwide. With a focus on tissue plasminogen activators (TPA), anticoagulants, and antiplatelets, healthcare providers aim to mitigate the impact of ischemic strokes. Hospitals and clinics are primary end users, particularly in regions like North America, Europe, and Asia-Pacific. Factors such as high blood pressure, cholesterol, and diabetes drive the demand for stroke therapeutics. Major players like Bristol-Myers Squibb Company and Johnson & Johnson Inc. dominate the market, with research institutions like Osaka Metropolitan University contributing to innovation. Despite pricing pressures and patent expiries, advancements in recombinant technology and robotic therapy offer hope for improving outcomes in stroke recovery.
|
Acute Ischemic Stroke Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
168 |
|
Base year |
2022 |
|
Historical year |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.72% |
|
Market growth 2023-2027 |
USD 1,524.49 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
5.49 |
|
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
|
Performing market contribution |
North America at 38% |
|
Key consumer countries |
US, Canada, UK, Germany, and China |
|
Competitive landscape |
Leading companies, Competitive Strategies, Consumer engagement scope |
|
Key companies profiled |
Athersys Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Medtronic Plc, NoNO Inc., SanBio Co Ltd., Stryker Corp., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd. |
|
Market Dynamics |
Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
|
Customization purview |
If our market research report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Market Segmentation by Distribution Channel
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Vendor Landscape
11 Vendor Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.